In an experiment aimed at testing the anticancer effects of pyrotinib combined with chrysin, it was confirmed that adding chrysin positively enhanced the inhibition of HER2-positive breast cancer growth both in vitro and in vivo, compared to pyrotinib alone [123]. Here, ERBB2 is linked to breast carcinoma.